AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00000331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Drug
Study NCT00000331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drug
Study NCT01397279 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intravenous glucose tolerance test
Description: Administration of a 30% weight-adapted glucose bolus intravenously.
Study NCT00812500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a medium protein diet.
Study NCT00812500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a higher protein diet.
Study NCT00537355 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate
Description: 6 weekly subcutaneous injections (escalating doses of 3 mcg to 30 mcg)
Study NCT00537355 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Histamine
Description: 6 weekly subcutaneous injections (escalating doses of 0.22 mcg to 1.1 mcg)
Study NCT01397279 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hyperinsulinemic euglycemic clamp
Description: Intravenous administration of 20% glucose and insulin over 3 hours
Study NCT01154140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment
Description: crizotinib 250mg orally continuous twice daily dosing
Study NCT01154140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment
Description: pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice
Study NCT00416195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Study NCT00416195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04130152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle
Study NCT04130152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.
Study NCT03646071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX108
Description: RX108
Study NCT02080338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic bracket slot system
Description: Orthodontic treatment using different orthodontic bracket slot systems
Study NCT02080338 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic bracket slot system
Description: Orthodontic treatment using different orthodontic bracket slot systems
Study NCT01047111 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure
Study NCT01394341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Daily sc. injection, individual dosage
Study NCT01394341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Daily sc. injection, individual dosage
Study NCT02740335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octaplex
Description: OCTAPLEX will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (\~3 units/kg/min), up to a maximum rate of 8.4 mL/min (\~210 units/min).
Study NCT02740335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beriplex P/N (Kcentra)
Description: Beriplex® P/N (Kcentra) will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (\~3 units/kg/min), up to a maximum rate of 8.4 mL/min (\~210 units/min).
Study NCT02541409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Direct acting antiviral agent used for the treatment of hepatitis C
Study NCT02541409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon alfa-2a
Description: Antiviral agent used for the treatment of hepatitis C
Study NCT02541409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
Study NCT02150252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bu-Yang-Huan-Wu Tang
Description: control group,Recruited patients should be received the placebo-BYHWT 3.0 g TID every day for continuously 6 weeks except ordinary medical care; 2) treatment group, the method is identical control group
Study NCT01544647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual spa protocol
Description: In the first group, 4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
Study NCT01544647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active spa protocol
Description: 4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
Study NCT01184612 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing; MI
Description: MI is a communication style defined as a collaborative, person-centred form of guiding to elicit and strengthen motivation to change. The method is based on four principles: showing empathy; developing discrepancy between the subject's current behaviour and an alternate, more desired, behaviour; reinforcing self-efficacy; and rolling with resistance to change. Client arguments for change are elicited and reinforced in an atmosphere that is empathic, collaborative and supportive of autonomy. The choice to change and the responsibility for change remain with the client.
Study NCT03780972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ONL1204
Description: Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection
Study NCT03780972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Injection
Description: Injection of study drug into the eye
Study NCT03780972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collection of ocular fluids
Description: vitreous and aqueous fluid collection by a tap and during vitrectomy
Study NCT00831402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligobs Maxiode
Description: The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
Study NCT00831402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: controll group
Description: 50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
Study NCT01043133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social marketing-based medical education intervention
Description: social-marketing based medical education intervention designed to influence medical student use of evidence-based templates. Led by physician instructor.
Study NCT02491970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/Formoterol
Study NCT02491970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/Salmeterol
Study NCT00789685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Beta
Description: Interferon Beta administered intravenously daily for 6 days. Doses of 0.12 MIU, 1.2 MIU, 2.7 MIU or 6.0 MIU (dose escalation phase) or 2.7 MIU (dose expansion phase) were administered.
Study NCT01415726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator
Description: For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 6 \~ 7 hrs.
Study NCT03057717 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2D ultrasound assessment
Description: 2D ultrasound assessment of fetal thymus size with measurements of the maximum transverse diameter and thymus perimeter
Study NCT00652717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg daily for 42 days.
Study NCT00652717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
Study NCT00652717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
Study NCT01949142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201
Description: Single, intratympanic injection
Study NCT01949142 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Simulated single, intratympanic injection
Study NCT01796275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core intervention program
Study NCT01796275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster session
Study NCT01796275 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control only (Tea gathering)
Study NCT02283476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar continuous intravenous infusion
Description: Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
Study NCT02283476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endostar routine intravenous infusion
Description: Endostar,7.5mg/m2, routine intravenous infusion 3-4 hours daily each cycle,21 days as one cycle, 4 cycles in total
Study NCT02283476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine,1000-1250mg/m2,i.v d1,d8 in each cycle,21 days as one cycle, 4 cycles in total
Study NCT00565604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short Catheter Delivery
Description: For treating incompetent perforator veins of the lower extremities
Study NCT03185494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19/22-CAR vector-transduced T cells
Description: genetically engineered lymphocyte therapy
Study NCT02584374 — intervention group
Intervention type: OTHER
Intervention: Venography with balloon occlusion test
Description: First, regular venography of the venous iliac tract will be performed. Second, a 16mm diameter balloon will be inflated in the common iliac vein and venography will be repeated.
Study NCT01709864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 (glycopyrronium bromide) as a powder for inhalation in single-dose capsules.
Study NCT01709864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
Study NCT04067596 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epiphysiodesis
Description: The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).~Under general anesthesia under scopic control, the growth cartilage will be approached from both sides in order to curse the growth zone.~This procedure is monitored throughout the procedure with iterative X-rays, to ensure complete curettage of the growth cartilage. The average duration of the intervention is 1 hour and a half.~At the end of the procedure, there will be on each limb, 2 operative scars on each side of the knee, 8 scars in all.~Closing will be done with resorbable stitches A simple dressing will be applied to each scar and a Zimmer splint in extension will be installed postoperatively to limit the painful mobilizations in acute phase.
Study NCT02283476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine,1000-1250mg/m2,i.v d1,d8 in each cycle,21 days as one cycle, 4 cycles in total
Study NCT02283476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin,75mg/m2,i.v d1 or d1-3 in each cycle,21 days as one cycle, 4 cycles in total
Study NCT02283476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin,75mg/m2,i.v d1 or d1-3 in each cycle,21 days as one cycle, 4 cycles in total
Study NCT04542278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: used to reduce inflammation
Study NCT01832883 — intervention group
Intervention type: DEVICE
Intervention: Pediatric Vision Scanner
Description: Subject is scanned with a 2.5 second pediatric vision scanner device test.
Study NCT00615810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atripla
Description: Open label once daily for oral administration to be taken on an empty stomach
Study NCT00615810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kivexa plus Sustiva
Description: Open label once daily for oral administration
Study NCT03454386 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management and Resilience Training Program
Description: This program targets attention and interpretation of events, people and the world through the skills of gratitude, compassion, acceptance, forgiveness and understanding of a higher meaning. The program involves two phases. The 4 week training phase begins with a group session that discusses the practices that can be used to enhance awareness and engagement through the principles listed above. Participants will receive twice weekly emails with videos that described a different practice for participants to use in their daily lives. The second phase is the sustain phase that is 8 weeks in duration. Participants are expected to continue using the daily practices learned during the training phase. Weekly emails will be sent with ways to incorporate these practices into their daily lives.
Study NCT03454386 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-Management Stress Reduction Program
Description: Program participants will be given a popular stress reduction book to read over a 12 week period. Upon completion of this, they will be enrolled in the online SMART program for 12 weeks.
Study NCT02849210 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot with Olea europaea pollen extract
Description: Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly increasing dose injections at the initiation phase plus 3 maintenance monthly injections.
Study NCT00703326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ramucirumab (IMC-1121B)
Description: Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
Study NCT00703326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: docetaxel
Description: Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
Study NCT00703326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
Study NCT00703326 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
Study NCT03115593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blind biopsy with a pipette
Description: Patients willing to participate to the study will benefit from a double biopsy. The first biopsy will be a blind biopsy performed by aspiration with a Cornier pipette.
Study NCT03115593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted biopsy using hysteroscopy
Description: During the same consultation, patients will benefit from a diagnostic hysteroscopy with vaginoscopy and saline (allowing a wash of the debris caused by the pipette biopsy), using a rigid hysteroscope of 4.3 mm equipped with an operator channel allowing the passage of a biopsy tong.
Study NCT02379455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive drug review
Description: 1) Geriatric assessment including medical history, physical examination, supplementary tests. The geriatric work-up will be aimed at evaluating whether current medications are indicated, whether the relevant conditions are satisfactorily compensated, whether the dosages are appropriate, whether the patient has symptoms that may in reality be adverse drug effects, and whether drug-drug interactions or drug-disease interactions are likely to occur. 2) Conference with common drug review. The project physician and the family physician will discuss the patient's drug list systematically. 3) Individualized clinical follow-up depending on the medication changes that have been done.
Study NCT04037800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SFUR-RARP
Description: Robotic-assisted radical prostatectomy with sustainable functional urethral reconstruction (SFUR)
Study NCT04037800 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard RARP
Description: Robotic-assisted radical prostatectomy with conventional RARP procedures.
Study NCT04581018 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health supplements
Description: 28 days of health supplements (synbiotic), 4g daily
Study NCT03734809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg every 3 weeks infusion
Study NCT04520906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
Study NCT02157571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prulifloxacin
Description: 600 mg/tablet, oral administration of a single tablet.
Study NCT02157571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: 500 mg/tablet, oral administration of a tablet daily.
Study NCT02157571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin Placebo
Description: Placebo of levofloxacin hydrochloride tablet, without active components.
Study NCT02157571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prulifloxacin placebo
Description: Placebo of prulifloxacin film-coated tablet without active components.
Study NCT01473017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based Guided Self-Help
Description: CBT-based booklet tailored to anxiety and/or depression in Type 2 Diabetes to enhance mood and Diabetes self-care
Study NCT01417104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: 150 mg/300mg
Study NCT01417104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mg/300mg
Study NCT01293942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab
Description: IXO plus bevacizumab regimen is given every 3 weeks (Q3W), in the following order: Bevacizumab (A): 7.5 mg/kg via IV infusion, day 1 Oxaliplatin (O): 100 mg/m2 via 2-hour IV infusion, day 1 Irinotecan (I): 160 mg/m2 via 1-hour IV infusion, day 1 Capecitabine (X): 950 mg/m2 twice daily PO, days 2 - 15
Study NCT03889847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibreoptic intubation with silicone double lumen tube
Description: Fibreoptic intubation with silicone double lumen tube
Study NCT03889847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibreoptic intubation with PVC double lumen tube
Description: Fibreoptic intubation with PVC double lumen tube
Study NCT01564277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasburicase
Description: Given IV
Study NCT01564277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: Given PO
Study NCT01851551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome Injection plus rituximab
Study NCT00246090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: E7389 1.4 mg/m\^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
Study NCT01896622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Impact on dabigatran PK/PD
Study NCT01896622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Impact on dabigatran PK/PD
Study NCT01589159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Drug:capecitabine 700mg/m2, twice daily on days 1-14.
Study NCT01589159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 30mg/m2, once daily on days 1-7.